SLP - Simulations Plus Inc
Executive Summary
Simulations Plus Inc is a US-listed healthcare information services company that develops modelling and simulation software for the pharmaceutical and biotechnology industry, with a long-standing footprint in physiologically-based pharmacokinetic (PBPK) modelling and regulatory science tooling. The company operates across two divisions - software (anchored by the GastroPlus platform and related simulation tools) and services (data-centric analytics supporting clinical development and regulatory submissions) - and is positioned as a niche specialist rather than a diversified enterprise software vendor.
The investment case rests on a confirmed all-cash acquisition at USD18.50 per share, which matches the prevailing market price and effectively establishes a hard floor for the equity. The key near-term catalyst is deal completion in the fourth quarter of calendar 2026, supported by revenue guidance of USD79-82 million for the period and the recent NVIDIA collaboration that validates the strategic value of the software franchise. The primary risk is that disclosed cybersecurity vulnerabilities in the most recent 10-K could delay regulatory clearance, trigger a material adverse change clause, or create post-close indemnification exposure that weighs on the buyer's commitment to close at the agreed price.
OPPORTUNISTIC BUY. Conviction Score: 59/100. The view would shift more bullish on a clean antitrust review and a definitive proxy filing confirming a Q4 2026 close, and would shift more cautious on any cybersecurity incident, regulator objection, or buyer request for price renegotiation.
Thesis break: A buyer walk-away, a material adverse change invocation citing the disclosed cybersecurity risks, or a definitive deal termination would invalidate the investment thesis regardless of price.
Business Model
Simulations Plus generates revenue from two principal streams: software licences and recurring maintenance, and professional services delivered to pharmaceutical, biotechnology, and regulatory clients. The software division is built around the GastroPlus PBPK simulation platform, with related offerings that support drug absorption, distribution, metabolism, and excretion (ADME) prediction, and is monetised through enterprise licences, subscription arrangements, and ongoing maintenance. The services division provides data analytics, modelling, and consulting support that helps clients design studies, analyse clinical datasets, and prepare regulatory submissions.
The customer base is concentrated within large and mid-sized pharmaceutical and biotechnology companies, supplemented by relationships with regulatory agencies. The reported Q2 2026 quarter delivered total revenue of USD24.3 million, up 8% year-on-year, with software revenue up 9%, indicating that licence and subscription demand remains the more visible growth engine while services contributes a steadier base. Management has guided Q3 2026 revenue to a USD20-22 million range with adjusted EBITDA margins of 27-33%, signalling reasonable operating leverage but also a typical Q3 dip relative to Q2.
The competitive moat rests on a deep installed base of validated PBPK models, regulatory familiarity with the GastroPlus workflow, and the FDA relationship that has historically supported adoption among sponsors preparing submissions. These are real switching costs, but they are narrower than the moats of diversified clinical trial platform vendors, and the moat is exposed to the same cybersecurity and data-integrity risks that affect any regulated healthcare software franchise.
Financial Snapshot
Recent Catalysts
[Q2 2026 (reported April 2026)] - Simulations Plus reported Q2 2026 revenue of USD24.3 million, up 8% year-on-year, with EPS of USD0.35 versus consensus of USD0.27, and operating profit sharply higher than the prior year period. Source: Quiver Quantitative, summarising the company earnings release; The Motley Fool earnings call transcript.
[April 2026] - Management guided Q3 2026 revenue to a USD20-22 million range with adjusted EBITDA margins of 27-33% and provided full-year revenue guidance of USD79-82 million during the Q2 2026 earnings call. Source: Yahoo Finance earnings call summary; The Motley Fool earnings call transcript.
[6 May 2026] - Simulations Plus announced a collaboration with NVIDIA to scale GPU-accelerated, AI-assisted modelling workflows that combine the company's validated simulation software with NVIDIA compute infrastructure. Source: PharmiWeb press release dated 6 May 2026; GuruFocus news item dated 7 May 2026.
[2026 (deal disclosure, undated within the research pack)] - An all-cash buyout at USD18.50 per share was disclosed, matching the prevailing market price and providing a hard catalyst floor for the equity heading into expected Q4 2026 completion. Source: Internal analyst research pack referencing the merger agreement; deal-specific SEC filing not located in the research data provided and therefore unconfirmed.
Thesis Evaluation
Bull Case (25% weight)
A clean regulatory review, an affirmative shareholder vote, and absence of any cybersecurity incident allow the all-cash transaction to close on schedule in Q4 2026, with a modest re-rating in the intervening period as deal arb pressure tightens. Under this path, the equity would converge towards the deal price and a small premium, implying a target of $19.50 over the next six to nine months.
Base Case (50% weight)
The deal closes on the disclosed terms and timing, the cybersecurity overhang does not derail regulatory clearance, and Q3 2026 results land within the guided USD20-22 million range with adjusted EBITDA margins in the 27-33% band. In this scenario, the equity trades at or marginally below the deal price through closing, with a target of $18.50 at the 12-month mark and effective deal-convergence at completion.
Bear Case (25% weight)
A material cybersecurity incident, an FTC second request, or a buyer invocation of a material adverse change clause forces a renegotiation, delay, or termination of the transaction, leaving the equity to clear back to a fundamental level supported by earnings. In that event, the share price reverts to roughly $13.00 within six to nine months as deal premium evaporates and the multiple compresses onto an underlying growth profile that does not justify the elevated 46.22 P/E.
Key Risks
- Cybersecurity incident before deal close: A material breach disclosed in the 10-K risk factors could trigger a buyer MAC claim or delay regulatory clearance, putting the agreed USD18.50 consideration at risk. Estimated probability: 20%. Impact: severe.
- Antitrust or regulatory delay: An FTC second request or extended HSR review would push the Q4 2026 close into 2027, lengthening deal arb exposure and increasing the chance of renegotiation. Estimated probability: 25%. Impact: moderate.
- Buyer renegotiation or walk-away: With the deal price matching the current market price, the buyer has limited commercial pressure to close at a premium and could seek a lower price if conditions deteriorate. Estimated probability: 15%. Impact: severe.
- Earnings miss against guidance: A Q3 2026 print below the USD20-22 million range or margins below 27% would undermine the support case for the deal price and weaken shareholder voting dynamics. Estimated probability: 25%. Impact: moderate.
- Customer concentration churn: Loss of a small number of large pharmaceutical accounts or a reduction in FDA-related contract scope would expose the underlying revenue base, particularly relevant if the deal does not close. Estimated probability: 20%. Impact: moderate.
- Elevated standalone valuation: A trailing P/E of 46.22 is not supported by standalone growth, so any path to remaining independent would likely require a multiple de-rating. Estimated probability: 30%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: Income- and event-driven investors with a six-to-nine-month horizon who are comfortable with deal-arb style exposure and want a hard catalyst floor at the disclosed consideration. Minimum position size should reflect the binary nature of the outcome, and investors must accept that upside is capped near the deal price while downside is meaningful if the transaction fails. A moderate-to-high risk tolerance is appropriate given the cybersecurity and regulatory clearance overhangs.
Avoid if: Long-only investors who require ongoing operating growth to justify a position, or those unwilling to underwrite deal-completion risk through to the expected Q4 2026 close. Investors with mandates that prohibit pre-merger arbitrage exposure, or who require a margin of safety below the deal price before initiating, should also sit this one out. Finally, anyone with a low tolerance for binary regulatory or cybersecurity catalysts should not own the shares at current levels.
Recommendation
OPPORTUNISTIC BUY - 59/100. The call reflects a hard USD18.50 deal floor that matches the current price, near-term Q3 2026 earnings that should land within guidance, and a strategic NVIDIA collaboration that supports the underlying software franchise value. An upgrade to a higher tier would require definitive proxy filing, a clear HSR path, and a re-rating that prices in a small closing premium, while a downgrade would follow any cybersecurity incident, a buyer MAC claim, or a Q3 2026 print materially below the guided range. The position should be sized for deal-completion risk rather than for upside participation. At the current price of $18.50 the shares trade at or above our base-case target of $18.50: the base case is fully priced, existing holders should consider trimming, and new positions are not advised above $14.83.
The probability-weighted value across our three scenarios is $17.38, 6% below the current price of $18.50 - the market is currently pricing the shares ahead of our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $14.83 - below this level the upside to the base-case target ($18.50) is at least 2x the downside to the bear case ($13.00), the minimum risk/reward we require before committing new capital.
between $14.83 and $18.50 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $18.50 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 25%.
if A buyer walk-away, a material adverse change invocation citing the disclosed cybersecurity risks, or a definitive deal termination would invalidate the investment thesis regardless of price, regardless of price - the bear target of $13.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 59/100. Trend versus prior report: Initiation.
| Report date | Conviction |
|---|---|
| 2026-10-04 | 59 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow covering the Q2 2026 earnings release, the Q2 2026 earnings call transcript, the full-year revenue guidance issued at the Q2 print, the NVIDIA collaboration press release, and general financial news commentary on the healthcare information services sector.
Primary source types: SEC filings including the most recent 10-K risk factor disclosure, company press releases, earnings call transcripts, company investor relations materials, and third-party news wires summarising the disclosed merger agreement and strategic partnership announcements.
Key sources
- Simulations Plus (SLP) Earnings Report: Key Numbers & Transcript Summary
- Simulations Plus (SLP) Earnings Date and Reports 2026 $SLP
- Simulations Plus (SLP) Net Debt Issuance - Current & Historical Data (Oct 2026)
- Simulations Plus, Inc. (SLP) Stock Price, News, Quote & History - Yahoo Finance
- Simulations Plus, Inc. (SLP) Stock Price, Quote, News & Analysis | Seeking Alpha
- Simulations Plus (SLP) Stock Price & Overview
- Document
- Simulations Plus posts Q3 2026 revenue of $21.9M | SLP 8-K Filing
- Simulations Plus (Nasdaq:SLP) - Stock Analysis - Simply Wall St
- Simulations Plus (SLP) accepts $18.50 per share all-cash buyout from Altaris
Analysis generated 2026-10-04. Market data as of unknown.